2019-nCoV RBD Antibody Rapid Test
- Risk class
- III
- Product type
- In Vitro Diagnostic
- Brand name
- Wondfo
- Commercial name
- 22-441-IVD Reagents/Testing Kits, Serology, Virus, Acute Respiratory Syndrome-Associated Coronavirus, COVID-19 IgG Antibodies
- Analysis ID
- ebf5f7e554d1e1b7437f95f63aa1aec2
- Registration date
- May 19, 2021
- Expiration date
- May 19, 2026
- City
- LIZHISHAN
- Country
- CHINA
- Address
- NO. 8, LIZHISHAN AV., SCIENCE CITY, LUOGANG DISTRICT, 510663, GUANGZHOU, P.R. CHINA
- Name
- GUANGZHOU WONDFO BIOTECH CO, LTD.
- Country
- CHINA
- Address
- AV ELOY ALFARO N32-656 AND RUSSIA TROYA BUILDING SECOND FLOOR
- Phone
- 6007782
THIS TEST IS DESIGNED TO HELP ASSESS THE ADAPTIVE HUMORAL IMMUNE RESPONSE TO 2019-NCOV
Access comprehensive regulatory information for 2019-nCoV RBD Antibody Rapid Test in the Ecuador medical device market through Pure Global AI's free database. This III medical device is registered under ARCSA ID ebf5f7e554d1e1b7437f95f63aa1aec2 and manufactured by GUANGZHOU WONDFO BIOTECH CO, LTD.. The device was registered on May 19, 2021.
This page provides complete registration details including product type (In Vitro Diagnostic), manufacturer information, authorized representative details, and regulatory compliance data from the official Ecuador ARCSA medical device database. Pure Global AI offers free access to Ecuador's complete medical device registry.